Improvements in or relating to organic compounds

Abstract

Disclosed is an encapsulated composition comprising at least one core-shell microcapsule. The at least one core-shell microcapsule comprises a core and a shell surrounding the core, the core comprising at least one benefit agent. The shell comprises a first and a second polyelectrolyte, the first and second polyelectrolyte forming a complex coacervate. The microcapsule comprises at least one interfacial enabler.

Description

[0001] This invention relates to an encapsulated composition, a method for preparing an encapsulated composition, an encapsulated composition obtainable by this method, the use of an interfacial enabler in obtaining the encapsulated composition, and the use of the encapsulated composition in obtaining a consumer product.

[0002] It is known to incorporate encapsulated beneficial agents into consumer products such as home care products, personal care products, and fabric care products. Functional materials include, for example, fragrances, cosmetic active ingredients, and bioactive ingredients such as biocides and pharmaceuticals. For the avoidance of any doubt, "beneficial agents" and "functional materials" are used as synonyms herein.

[0003] Microcapsules particularly suitable for delivering such beneficial agents are core-shell microcapsules, wherein the core contains the functional material and the shell is impermeable or partially impermeable to the core. Typically, these microcapsules are used in aqueous media, and the encapsulated beneficial agent is hydrophobic. A wide range of shell materials can be used, provided that the shell material is impermeable or partially impermeable to the encapsulated functional material.

[0004] Among these beneficial agents, fragrances are encapsulated for a number of reasons. Microcapsules can isolate fragrances from and protect them from external suspension media, such as consumer product matrices, in which fragrances may be incompatible or unstable. Microcapsules are also used to facilitate the deposition of fragrance ingredients onto substrates such as skin, hair, fabrics, or hard household surfaces. They can also serve as a means of controlling the spatiotemporal release of fragrances.

[0005] Microcapsules containing a hydrophobic liquid core are surrounded by a cross-linked gelatin-based simple or complex aggregate layer, which is well known in the art. For example, US6045835 discloses a method for encapsulating a fragrance or flavoring into a microcapsule having a hydrogel shell containing a gelatin and an oil core. In US8088403, B2 gelatin is preferred over other proteins due to its favorable physicochemical properties.

[0006] However, gelatin is an animal-derived protein, typically obtained from fish, pork, beef, and / or poultry. Today, consumers are increasingly concerned about the use of materials derived from animal sources, especially when these materials are used in body care applications.

[0007] Therefore, overcoming the aforementioned drawbacks of the prior art is the fundamental problem of this invention. In particular, providing protein-based encapsulated compositions of the type described above, made from non-animal-derived materials, is a fundamental problem of this invention. The capsules should exhibit good stability during manufacturing and storage, and beneficial release characteristics in application. Furthermore, the compositions should be capable of being produced in a safe, stable, and cost-effective process.

[0008] These issues are addressed through the subject matter of the independent claims.

[0009] In a first aspect, the present invention relates to a composition comprising at least one core-shell microcapsule. The at least one core-shell microcapsule comprises a core and a shell surrounding the core, the core comprising at least one beneficial agent. The shell comprises first and second polyelectrolytes, the first and second polyelectrolytes forming a composite cohesive layer. The microcapsule comprises at least one interface enabler.

[0010] In this context, an "interface enabler" refers to a substance that has the ability to interact with at least one polyelectrolyte at the phase interface of the core composition to promote shell formation. Without being bound by any theory, this interaction can be achieved through dispersive forces, electrostatic forces, or hydrogen bonds. Furthermore, covalent bonds are also included in this term.

[0011] The core of the core-shell microcapsule is made of a core composition. This core composition is particularly immiscible with water.

[0012] The term "substantially immiscible with water" means that when the core composition is mixed with water, even under vigorous stirring, at least 95 wt.-%, preferably at least 99 wt.-%, of the core composition phase separates from the water phase immediately or gradually after stirring is stopped.

[0013] Preferably, the amount of the core composition is less than the amount of the aqueous phase, such that when emulsified with the aqueous phase, the core composition forms a dispersed phase in the aqueous phase, typically in the form of core composition droplets.

[0014] The term "condensation layer" refers to a polyelectrolyte-rich droplet that coexists with an aqueous, low-polyelectrolyte continuous phase. The droplets aggregate at the interface to form the interfacial layer.

[0015] In the context of this invention, condensate droplets aggregate at the interface between the core composition and the aqueous phase. As a result, a stable core-shell capsule is formed, comprising core composition droplets surrounded by condensate droplets. These stabilize the composition droplets and form the capsule wall.

[0016] The term "composite coagulation" or "composite coagulation layer" refers to the formation of an interface layer containing a mixture of polyelectrolytes.

[0017] The phenomenon of composite aggregation can be observed under an optical microscope, marked by the appearance of rings around the core composition droplets. These rings consist of the aforementioned polyelectrolyte-rich phase, which has a different refractive index than the surrounding aqueous phase.

[0018] The recombination of two polyelectrolytes is typically induced by bringing the two polyelectrolytes to their isoelectric points, which are points where the total net charge of the two polyelectrolytes is zero or close to zero, thereby inducing recombination. This can be achieved by changing the salt concentration, or, in the case of amphoteric polyelectrolytes such as proteins, by changing the pH of the medium.

[0019] It has been found that the efficiency of co-aggregation between two polyelectrolytes can be significantly improved by using an interface enabler. In particular, this significant improvement makes it possible to obtain microcapsules based on strictly vegetarian proteins with performance comparable to gelatin-based microcapsules. Furthermore, by using this interface enabler, microcapsules with a volume average diameter of less than 25 μm and even less than 10 μm can be obtained, which would otherwise be difficult to achieve.

[0020] In a particular embodiment of the invention, the core comprises a liquid core composition. An interface enabler is then soluble in the core composition or derived from a material soluble in the core composition.

[0021] Preferably, the interface enabler is a multifunctional molecule or derived from a multifunctional molecule, and more preferably a bifunctional molecule. Multifunctional molecules have been found to be particularly suitable for promoting shell formation.

[0022] Without being bound by any theory, if the interface enabler is a multifunctional molecule or derived from a multifunctional molecule, it can be a crosslinking agent for crosslinking the first and / or second polyelectrolytes.

[0023] For co-aggregation to occur, the first and second polyelectrolytes preferably have opposite charges at a given pH. As described above, co-aggregation occurs when the total pure charge of the two polyelectrolytes is zero or close to zero.

[0024] In the following text, the first and second polyelectrolytes are interchangeable, meaning that the term "first" does not take precedence over the term "second".

[0025] The first polyelectrolyte is preferably an amphoteric polyelectrolyte. An advantage of the amphoteric polyelectrolyte is that it has a variable charge, which depends on the pH value. Therefore, changing the pH can control the state of the polymer in water (hereinafter referred to as the "aqueous phase"). Thus, depending on the pH, the polymer can be more or less cationic, more or less anionic, or even change from a cationic polyelectrolyte to an anionic polyelectrolyte, and vice versa. The pH at which the polymer has zero charge is called the isoelectric point.

[0026] In a preferred embodiment, the isoelectric point of the amphoteric polyelectrolyte is below pH 7, preferably below pH 6, more preferably below pH 5.5, and even more preferably below pH 5.0. Under these conditions, the amphoteric polyelectrolyte undergoes an anionic-to-cationic transition, which can be easily triggered using conventional Brønsted acids. Simultaneously, as described below, the charge of the second polyelectrolyte is also controlled by the pH of this region. This situation is particularly favorable for complex coagulation.

[0027] To obtain a slurry with a practically acceptable amount of microcapsules, the first and second polyelectrolytes preferably have a solubility in water at pH 7 ± 0.5 and room temperature greater than 5 wt.-%, preferably greater than 10 wt.-%. In the context of this invention, the term "water" includes deionized water and tap water.

[0028] In a preferred embodiment of the invention, the amphoteric polyelectrolyte is a protein, particularly a protein derived from a strict vegan diet. Proteins are versatile amphoteric polyelectrolytes due to their chemical and conformational diversity, balance of hydrophobic and hydrophilic properties, and electrostatic characteristics. Such properties are particularly advantageous for complex aggregation. In today's social and ethical context, the fact that strict vegan proteins are not derived from animals is an advantage.

[0029] In a particularly preferred embodiment, the protein derived from a vegan source is selected from soy protein, pea protein, rice protein, and hemp protein, with soy protein being preferred. These proteins can be used directly or in a denatured form. Protein denaturation typically involves changes in the secondary, tertiary, and quaternary structures of a protein, transforming a highly functional and specialized macromolecule into a material usable for a wide range of applications. Denaturation is known to be induced by, for example, temperature, pH, ionizing radiation, shear stress, water-based structural disruptors, and detergents. Proteins can be isolated from vegan sources using known methods such as extraction and centrifugation.

[0030] Protein isolates may contain substances insoluble in water and may precipitate or impart turbidity to aqueous solutions containing proteins. In a particular embodiment of the invention, an aqueous solution containing a nominal percentage of 5 wt.-% protein, particularly from strictly vegan sources, contains less than 0.1 wt.-%, preferably less than 0.05 wt.-% insoluble material, based on the total weight of the solution. "Nominal percentage" refers to the weight of protein added to the aqueous phase at the start of the dissolution process.

[0031] As an alternative to protein isolates that typically have a protein content of 80 to 95 wt.%, protein concentrates with a lower protein content (e.g., about 70 wt.%) can also be used. However, the use of protein isolates is preferred to minimize the possibility of contamination from impurities during encapsulation. If a protein concentrate is used, an aqueous solution containing a nominal percentage of 5 wt.% protein, particularly from strictly vegan sources, contains less than 0.2 wt.%, preferably less than 0.1 wt.%, of insoluble material based on the total weight of the solution.

[0032] In a preferred embodiment of the invention, the second polyelectrolyte is a polysaccharide, preferably a polysaccharide containing a carboxyl group. Besides the fact that polysaccharides are also of biological origin and strictly vegan (a considerable advantage relative to the invention), carboxyl-containing polysaccharides are particularly suitable for complex coagulation-mediated microencapsulation. On the one hand, these polymers may have the ability to accumulate at the interface and act as emulsifiers or co-emulsifiers. On the other hand, their carboxyl groups may be more or less deprotonated, depending on pH, thereby allowing modulation of their anionic properties and their ability to establish electrostatic interactions with proteins.

[0033] Polysaccharides containing carboxylic acid groups can contain uronic acid units, particularly hexuronic acid units. Polysaccharides containing uronic acid units, especially hexuronic acid units, are widely available in nature. Hexuronic acid units can be selected from galacturonic acid units, glucuronic acid units, particularly 4-O-methyl-glucuronic acid units, guluronic acid units, and mannuronic acid units.

[0034] Polysaccharides containing carboxylic acid groups can be branched. Branched polysaccharides containing carboxylic acid groups have the advantage of forming a more compact network structure than linear polysaccharides, which can improve the impermeability of the encapsulation shell, thereby reducing leakage and improving encapsulation efficiency.

[0035] Carboxyl groups can also be chemically grafted onto polysaccharides. For example, carboxymethyl cellulose can be obtained by reacting cellulose with chloroacetic acid or its sodium salt under alkaline conditions. In this reaction, the C2, C3, and C6 hydroxyl groups can be replaced by carboxyl functional groups.

[0036] In a preferred embodiment of the invention, the polysaccharide containing carboxylic acid groups is selected from carboxymethyl cellulose, gum arabic, alginate, pectin, hyaluronic acid, xanthan gum, gellan gum, and their salts with monovalent alkali metals. In the context of this invention, carboxymethyl cellulose (CMC) and sodium carboxymethyl cellulose are particularly preferred because these modified celluloses are less prone to quality fluctuations compared to unmodified polysaccharides. Furthermore, the degree of substitution (DS) of CMC, i.e., the average number of carboxylic acid or carboxylic ester groups divided by the number of pyranose units in the CMC macromolecule, can be higher than the degree of substitution of other polysaccharides containing carboxylic acid groups. For example, gum arabic consists of only 15% to 16% (DS = 0.15-0.16) glucuronic acid, while in CMC, one pyranose unit can contain up to three carboxyl groups, typically between 0.4 and 1.5 (DS = 0.4-1.5). CMCs with a DS below 0.4 are small amounts of solids, while higher grades of CMC are difficult to manufacture industrially.

[0037] Preferably, the molecular weight of the polysaccharide is selected in such a way that the polysaccharide macromolecules are large enough to form a viscous aggregate layer, and low enough to prevent the slurry from becoming too viscous.

[0038] In a particularly preferred embodiment of the invention, the carboxymethyl cellulose and / or sodium carboxymethyl cellulose has a molecular weight of 50,000 to 250,000 g / mol, preferably 75,000 to 125,000 g / mol, and a degree of substitution of 0.5 to 1.5, preferably 0.6 to 1.1.

[0039] The ratio of the second polyelectrolyte to the first polyelectrolyte is determined by their respective electrostatic charges and the necessity of forming an electrostatically neutral polymer-polymer complex within the pH range of the complex coagulation. This ratio is typically determined experimentally.

[0040] When the first polyelectrolyte is a protein and the second polyelectrolyte is carboxymethyl cellulose and / or sodium carboxymethyl cellulose, the weight ratio of the carboxymethyl cellulose or sodium carboxymethyl cellulose to the protein, preferably a protein derived from a strictly vegan source, more preferably soy protein, is 0.05 to 0.2, preferably 0.08 to 0.12.

[0041] Preferably, the interface enabler is derived from a diacid or a dialdehyde, and more preferably from an aromatic dialdehyde. However, while diacids effectively improve encapsulation, the resulting microcapsules have lower thermal stability than those obtained using dialdehydes as interface enablers.

[0042] Dicarboxylic acids can be selected from 1,3-propanedicarboxylic acid (glutaric acid), 1,4-butanedicarboxylic acid (adipic acid), 1,5-pentanedicarboxylic acid (heptanedicarboxylic acid), and 1,4-cyclohexanedicarboxylic acid.

[0043] Cyclic dialdehydes can be selected from o-phthalaldehyde (1,2-phenylenedialdehyde), iso-phthalaldehyde (1,3-phenylenedialdehyde), terephthalaldehyde (1,4-phenylenedialdehyde), 1,2-cyclohexanedialdehyde, 1,3-cyclohexanedialdehyde, 1,4-cyclohexanedialdehyde, cyclopentane-1,3-dialdehyde, [1, [1'-biphenyl]-3,4'-dicarboxaldehyde, [1,1'-biphenyl]-3,3'-dicarboxaldehyde, [1,1'-diphenyl]-3,2'-dicarboxaldehyde, 9,10-anthracene dicarboxaldehyde, 4,4'-biphenyl dicarboxaldehyde, furan-2,5-dicarboxaldehyde, and 1,4-bis(X-formyl-phenoxy)alkane, wherein X = 2, 3, or 4, and the alkane residue comprises 2 to 6 carbon atoms, more specifically 4 carbon atoms, 1,4-diformylpiperazin, and 2,2'-bipyridine-4,4'-dicarboxaldehyde. More preferably, the cyclic dialdehyde is an aromatic dialdehyde selected from o-phthalaldehyde (1,2-phenylenedialdehyde), iso-phthalaldehyde (1,3-phenylenedialdehyde), terephthalaldehyde (1,4-phenylenedialdehyde), [1,1'-biphenyl]-3,4'-dialdehyde, [1,1'-biphenyl]-3,3'-dialdehyde, [1,1'-biphenyl]-3,2'-dialdehyde, 9,10-anthracene dialdehyde, and 4,4'-biphenyl dialdehyde.

[0044] In a preferred embodiment, the interface enabler is or is derived from a dialdehyde selected from 1,3-phenylenedialdehyde, 1,3-cyclohexanedialdehyde, cyclopentane-1,3-dialdehyde, furan-2,5-dialdehyde, and 1,4-dicarboxylpiperazine, even more preferably from 1,3-phenylenedialdehyde and 1,4-dicarboxylpiperazine, and still more preferably from 1,3-phenylenedialdehyde. Interface enablers with these characteristics are readily soluble in the core composition, and thus particularly advantageous for obtaining suitable microcapsules of the present invention.

[0045] In a preferred embodiment of the invention, the interface enabler is present at a level of 0.1 to 5 wt.-%, preferably 0.5 to 2.0 wt.-%, and still more preferably 0.75 to 1.5 wt.-%, based on the weight of the core composition. If the level of the interface enabler is too low, microcapsules with the desired properties cannot be formed: the resulting microcapsules are too large and thermally unstable. On the other hand, increasing the level of the interface enabler above a certain level, such as 2 wt.-%, does not improve the properties of the microcapsules and may be detrimental to the quality of the core composition. For example, if the core component is a fragrance, an excessive amount of interface enabler may affect the olfactory properties of such a fragrance. Furthermore, at higher levels, such as above 5%, solubility problems may occur.

[0046] When the weight ratio of the interface enabler to protein (preferably a protein derived from a strict vegan source, or even more preferably soy protein) is 0.01 to 0.1, preferably 0.02 to 0.08, or even more preferably 0.03 to 0.07, the best performance in terms of microcapsule diameter, encapsulation efficiency and microcapsule stability can be obtained.

[0047] The beneficial agents contained in the core or core composition may be selected from fragrance ingredients, cosmetic ingredients, and bioactive ingredients.

[0048] In a particular embodiment of the invention, the core composition comprises at least one fragrance ingredient. A comprehensive list of fragrance ingredients that can be encapsulated according to the invention can be found in fragrance literature such as "Perfume & Flavor Chemicals," S. Arctander (Allured Publishing, 1994). The fragrance encapsulated in this invention preferably comprises a fragrance ingredient selected from the following: acetyl isoeugenol ((E)-2-methoxy-4-(prop-1-en-1-yl)phenyl acetate); adocal (2,6,10-trimethylundec-9-enal); AGRUMEX (2-(tert-butyl)cyclohexyl acetate); C10 decanal (decanal); C11 MOA aldehyde (2-methyldecanal); C11 undecenal (undec-10-enal); C110 undecanal (undecanal); C12 lauraldehyde (dodecanal); C12 MNA aldehyde (2-methylundecanal); C8 octanal (octanal); C9 isononanal (3,5,5-trimethylhexanal); food-grade C9 nonanal (nonanal); C90 nonenal ((E)-non-2-enal); ISO C11 aldehyde ((E)-undec-9-enal); rutinal ((E)-dodec-2-enal); allyl pentyl glycolate (2-(3-methylbutoxy)acetic acid prop-2-enyl ester); allyl hexanoate (prop-2-enyl hexanoate); allyl cyclohexyl propionate (3-cyclohexyl propionate prop-2-enyl ester); allyl heptanate (prop-2-enyl heptanate); amber core (1-((2-(tert-butyl)cyclohexyl)oxy)but-2- - alcohol); ambroxan acetal (3,8,8,11a-tetramethyldodecylhydro-1H-3,5a-epoxynaphtho[2,1-c]oxacycloheptatriene); premium ambroxol (1,3,4,5,6,7-hexahydro-β,1,1,5,5-pentamethyl-2H-2,4a-methylenenaphthalene-8-ethanol); safflower lactone ((Z)-oxacycloheptadec-10-en-2-one); ambroxan furan ((3aR,5aS,9aS,9b R)-3a,6,6,9a-tetramethyl-2,4,5,5a,7,8,9,9b-octahydro-1H-benzo[e][1]benzofuran); pentyl butyrate (pentyl butyrate); pentyl cinnamaldehyde ((Z)-2-benzylheptanal); pentyl salicylate (pentyl 2-hydroxybenzoate); synthetic anethole ((E)-1-methoxy-4-(prop-1-en-1-yl)benzene); anisyl acetate (4-methoxybenzyl acetate); alfalfa Mannyl ester (1-(3,3-dimethylcyclohexyl)ethyl formate); anisaldehyde-p-cresol (4-methoxybenzaldehyde); nerolidin ((E)-2-((7-hydroxy-3,7-dimethyloctyl)amino)methyl benzoate); BELAMBRE ((1R,2S,4R)-2'-isopropyl-1,7,7-trimethylspiro[bicyclo[2.2.1]heptane-2,4'-[1,3]dioxane]); benzaldehyde (benzaldehyde);Benzyl acetate (Benzyl acetate); Benzylacetone (4-Phenylacetone-2-one); Benzyl benzoate (Benzyl benzoate); Benzyl salicylate (Benzyl 2-hydroxybenzoate); Berryfu (Ethyl 6-acetoxyhexanoate); Bicyclononolactone (Octahydro-2H-chromene-2-one); Ethoxycyclododecyloxymethane ((ethoxymethoxy)cyclododecane); Bosley ((1S,2R,5R)-2-ethoxy-2,6,6-trimethyl-9-methylenebicyclo[3.3.1]nonane); Borneol crystals ((1S,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ol); Borneol acetate ((2S,4S)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl ester) ); Bojiehong aldehyde (3-(4-(tert-butyl)phenyl)propanal); Butyryl lactate (1-butoxy-1-oxoprop-2-yl butyrate); p-Butylcyclohexyl acetate (4-(tert-butyl)cyclohexyl acetate); sec-Butylquinoline (2-(2-methylpropyl)quinoline); Synthetic camphor ((1S,4S)-1,7,7-trimethylbicyclo[2.2.1]hep-2-one); Carvacrol (5-isopropyl-2-methylphenol); L-carvacrol ((5R)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-one); Cashmereone (1,1,2,3,3-pentamethyl-2,3,6,7-tetrahydro-1H-indene-4(5H)-one); CASSYRANE (5-tert-butyl- 2-Methyl-5-propyl-2H-furan); cypressene ((1S,8aR)-1,4,4,6-tetramethyl-2,3,3a,4,5,8-hexahydro-1H-5,8a-methylenechalcogenide); cypressene acetate ((1S,6R,8aR)-1,4,4,6-tetramethyloctahydro-1H-5,8a-methylenechalcogenide-6-yl ester); cypressene methyl ether ((1R,6S,8aS)-6-methoxy-1,4,4,6-tetramethyloctahydro-1H-5,8a-methylenechalcogenide); allyl ionone ((E)-1-(2,6,6-trimethylcyclohexyl-2-en-1-yl)hept-1,6-dien-3-one); synthetic cinnamyl alcohol ((E)-3-phenylpropanol- 2-en-1-ol); cinnamaldehyde ((2E)-3-phenylprop-2-enal); cinnamyl acetate ((E)-3-phenylprop-2-en-1-yl acetate); cis-jasmone ((Z)-3-methyl-2-(pent-2-en-1-yl)cyclopent-2-enone); cis-3-hexenol ((Z)-hex-3-en-1-ol); citral ((E)-3,7-dimethyloct-2,6-dienal); citral diethyl acetal ((Z)-1,1-diethoxy-3,7-dimethyloct-2,6-diene); citronellol (3,7-dimethyloct-6-enal); citronellol (3,7-dimethyloct-6-en-1-ol); citronellol acetate (3,7-dimethyloct-6-en-1-yl acetate);Citronellol formate (3,7-dimethyloct-6-en-1-yl formate); Citronellol (3,7-dimethyloct-6-en-acrylonitrile); Dodecanone; Corona alcohol (4-cyclohexyl-2-methylbut-2-ol); Musk ((Z)-3-methylcyclotetradec-5-enone); Coumarin crystals (2H-chromen-2-one); p-cresol acetate ((4-methylphenyl) acetate); p-cresol methyl ether (1-methoxy-4-methylbenzene); Musk ((Z)-3-methylcyclotetradec-5-enone); Cuminone (4-isopropylbenzonitrile); Privet aldehyde (2,4-dimethylcyclohexyl-3-en-1-carboxaldehyde); Rabbit ear grass aldehyde (3-(4-isopropylphenyl)-2-methylpropanal); Cyclocarya paliurus Ester (2-(cyclohexyloxy)acetic acid allyl ester); Cyclohexyl ethyl acetate (2-cyclohexyl ethyl acetate); Cyclohexyl salicylate (2-hydroxybenzoic acid cyclohexyl ester); Cyclohexanic aldehyde (8,8-dimethyl-1,2,3,4,5,6,7,8-octahydronaphthalene-2-aldehyde); Cymene (1-methyl-4-prop-2-ylbenzene); Tufurenone ((E)-1-(2,6,6-trimethylcyclohex-1,3-dien-1-yl)but-2-en-1-one); Alpha-Tufurenone ((E)-1-(2,6,6-trimethylcyclohex-2-en-1-yl)but-2-en-1-one); Butylated Tufurenone (1-(2,6,6-trimethyl-1-cyclohex-3-en-yl)but-2-en-1-one); Propyl-Decanter Lactone (5-hexyloxacyclopentan-2-one); trans-4-decenal ((E)-dec-4-enal); DELPHONE (2-pentylcyclopentanone); δ-3-carene ((1S,6S)-3,7,7-trimethylbicyclo[4.1.0]hept-3-ene); dihexyl fumarate (dihexyl-but-2-enediol); dihydroanisole (1-methoxy-4-propylbenzene); dihydrojasmone (3-methyl-2-pentylcyclohex-2-enone); dihydromyrcenol (2,6-dimethyloct-7-en-2-ol); dimethyl anthranol (2-(methylamino)benzoate); dimethylbenzylmethanol (2-methyl-1-phenylprop-2-ol); dimethyl benzyl acetate (acetic acid) 2-Methyl-1-phenylprop-2-yl ester); dimethyl benzyl butyrate (2-methyl-1-phenylprop-2-yl butyrate); dimethyl octenone (4,7-dimethyl oct-6-en-3-one); dimethyl heptanol (2,6-dimethyl hep-2-ol); limonene (1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene); diphenyl ether (oxodiphenyl); butyl dodecanolide (6-heptyltetrahydro-2H-pyran-2-one); propionyl dodecanolide (5-octyloxacyclopentan-2-one); dodecenoal ((E)-dodecenoal); Doubicarr ((E)-4-((3aS,7aS)-hexahydro-1H-4,7-methyleneindene-5(6H)-ylidene)butanol);Ebony alcohol ((E)-3-methyl-5-(2,2,3-trimethylcyclopent-3-en-1-yl)pent-4-en-2-ol); ESTERLY (ethyl cyclohexyl carboxylate) carboxylate); ethyl acetate; ethyl acetoacetate (ethyl 3-oxobutyrate); ethyl cinnamate (ethyl 3-phenylprop-2-enoate); ethyl hexanoate (ethyl hexanoate); ethyl linalool ((E)-3,7-dimethylnonano-1,6-dien-3-ol); ethyl linaloacetate ((Z)-3,7-dimethylnonano-1,6-dien-3-yl acetate); ethyl maltol (2-ethyl-3-hydroxy-4H-pyran-4-one); ethyl methyl-2-butyrate (ethyl 2-methylbutyrate); ethyl octanoate (ethyl octanoate); ethyl heptanoate (ethyl heptanoate); ethyl phenyl glycidyl ester (3-oxobutyrate); ethyl cinnamate (ethyl 3-phenylprop-2-enoate); ethyl heptanoate (ethyl heptanoate); ethyl phenyl glycidyl ester (3-oxobutyrate); ethyl cinnamate (ethyl 3- ... 2-phenylethylene oxide-2-carboxylate); ethyl saffronate (2,6,6-trimethylcyclohexane-1,3-diene-1-carboxylate); ethyl vanillin (3-ethoxy-4-hydroxybenzaldehyde); ethylene brassinolate (1,4-dioxane-5,17-dione); eucalyptol ((1s,4s)-1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane); eugenol (4-allyl-2-methoxyphenol); synthetic oak (2,4-dihydroxy-3,6-dimethylbenzoate); fennel acetate ((2S)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl acetate); Furazolidone ((1S,2R,4R)-1,3,3-trimethylbicyclo[2.2.1]hepta-2-ol); anisaldehyde (3-(4-methoxyphenyl)-2-methylpropanal); FIXAMBRENE (3a,6,6,9a-tetramethyldodecano[2,1-b]furan); tuna musk (1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthyl-2-yl)acetone); hairyl aldehyde (3-(4-ethylphenyl)-2,2-dimethylpropanal); anthocyanin (3-(3-isopropylphenyl)butanal); FLORIDILE ((E)-undec-9-enonitrile); tricyclodecanoic acid Enal (propionic acid (3aR,6S,7aS)-3a,4,5,6,7,7a-hexahydro-1H-4,7-methyleneinden-6-yl ester); floppy (2,4,6-trimethyl-4-phenyl-1,3-dioxane); lily of the valley pyran HC (tetrahydro-4-methyl-2-(2-methylpropyl)-2H-pyran-4-ol); menthone (2-(sec-butyl)cyclohexanone); apple ester (2-(2-methyl-1,3-dioxacyclopentan-2-yl)ethyl acetate); fructose ester ((3aS,4S,7R,7aS)-octahydro-1H-4,7-methyleneinden-3a-carboxylic acid ethyl ester); fruit nitrile (2-methyldecanoic acid);Gleconone (1-(5,5-dimethylcyclohexyl-1-en-1-yl)pent-4-en-1-one); Styrax ester acetate (1-phenylethyl acetate); Tricyclodecenyl isobutyrate (2-methylpropionic acid (3aR,6S,7aS)-3a,4,5,6,7,7a-hexahydro-1H-4,7-methyleneinden-6-yl ester); Geraniol ((E)-3,7-dimethyloct-2,6-dien-1-ol); Geraniol acetate ((E)-3,7-dimethyloct-2,6-dien-1-yl acetate); Geraniol crotonate (but-2-enoic acid (E)-3,7-dimethyloct-2,6-dien-1-yl ester); Geraniol isobutyrate (2-methylpropionic ... En-1-yl ester); Chihuatan (ethyl 2-ethyl-6,6-dimethylcyclohexyl-2-encarboxylate); Cyclopentadene lactone ((E)-oxacyclohexadecano-12-en-2-one); Methyl dihydrojasmone (methyl 3-oxo-2-pentylcyclopentane acetate); Jasminal crystals (benzo[d][1,3]dioxacyclopenten-5-carboxaldehyde); Shampoo ester ((2S)-3-isopropylbicyclo[2.2.1]hept-5-en-2-carboxylate); trans-2-hexenal ((E)-hex-2-enal); cis-3-hexenol ((Z)-hex-3-en-1-ol); cis-3-hexenyl acetate ((Z)-hex-3-en-1-yl acetate); cis-3-hexenyl butyrate ((Z)-hexenyl butyrate) -3-en-1-yl ester); cis-3-hexenyl isobutyrate (2-methylpropionic acid (Z)-hex-3-en-1-yl ester); cis-3-hexenyl salicylate (2-hydroxybenzoic acid (Z)-hex-3-en-1-yl ester); hexyl acetate (hexyl acetate); hexyl benzoate (hexyl benzoate); hexyl butyrate (hexyl butyrate); hexyl cinnamaldehyde ((E)-2-benzyl octanal); hexyl isobutyrate (2-methylpropionic acid hexyl ester); hexyl salicylate (2-hydroxybenzoic acid hexyl ester); hydroxycitronellol (7-hydroxy-3,7-dimethyloctanal); indole (4,4a,5,9b-tetrahydroindo[1,2-d][1,3]dioxin); indole (1H-indole); indoleene (8,8-di(1H-indole) -3-yl)-2,6-dimethyloct-2-ol); ethyl ionone ((E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one); angelone ((E)-3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one); methyl ionone ((E)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one); methyl irisone ((E)-4-(2,5,6,6-tetramethylcyclohex-2-en-1-yl)but-3-en-2-one); ambergris (1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthyl-2-yl)ethyl ketone);Isoamyl acetate (3-methylbutyl acetate); Isoamyl butyrate (3-methylbutyl butyrate); Isobutylmethoxypyrazine (2-methylpropyl 3-methoxypyrazine); Isocyclocitral (2,4,6-trimethylcyclohexyl-3-encarboxaldehyde); Isoeugenol ((E)-2-methoxy-4-(prop-1-en-1-yl)phenol); Isojasmine B11 (2-hexylcyclopentan-2-en-1-one); Isomenthone DL (2-isopropyl-5-methylcyclohexanone); Isononyl acetate (3,5,5-trimethylhexyl acetate); Isopropyl methyl-2-butyrate (2-methylbutyrate); Isopropylquinoline (6-isopropylquinoline); Isomethylionone ((E)-3-methyl-4-(2,6, 6-Trimethylcyclohexyl-2-en-1-yl)but-3-en-2-one); Tricyclodecenyl acetate ((3aR,6S,7aS)-3a,4,5,6,7,7a-hexahydro-1H-4,7-methyleneinden-6-yl ester); Cis-jasmone ((Z)-3-methyl-2-(pent-2-en-1-yl)cyclopent-2-enone); Jasmone ester (3-butyl-5-methyltetrahydro-2H-pyran-4-yl ester); Jasmone pyran (3-pentyltetrahydro-2H-pyran-4-yl ester); Javanese sandalwood ((1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]cyclohexyl-3-yl)methyl)cyclopropyl)methanol); High aromatics ((Z)-3,4, 5,6,6-Pentamethylhept-3-en-2-one); lactone (8-isopropyl-1-oxaspiro[4.5]dec-2-one); leaf alcohol acetal ((Z)-1-(1-ethoxyethoxy)hex-3-ene); citric acid nitrile ((2E,6Z)-3,7-dimethylnonan-2,6-dienonitrile); chlorophen ((Z)-hex-3-en-1-ylmethyl carbonate); lily aldehyde (3-(4-(tert-butyl)phenyl)-2-methylpropanal); #N / A linalool (3,7-dimethyloct-1,6-dien-3-ol); linalool oxide (2-(5-methyl-5-vinyltetrahydrofuran-2-yl)prop-2-ol); linalyl acetate (3,7-dimethyloct-1,6-dienyl acetate) -3-yl ester); MAHONIAL ((4E)-9-hydroxy-5,9-dimethyl-4-decenal); maltol (3-hydroxy-2-methyl-4H-pyran-4-one); maltol isobutyrate (2-methylpropionic acid 2-methyl-4-oxo-4H-pyran-3-yl ester); chamomile ester (2-methylvalerate ethyl ester); maltol ((4-isopropylcyclohexyl)methanol); rose alcohol (3-methyl-5-phenylpentan-1-ol); melonaldehyde (2,6-dimethylheptane-5-enal); #N / A#N / A mercapto-8-menthane-3-one (mercapto-p-menthane-3-one); methyl anthranilate (2-aminobenzoate methyl ester); methyl benzoate (methyl benzoate);Methyl cypress ketone (1-((1S,8aS)-1,4,4,6-tetramethyl-2,3,3a,4,5,8-hexahydro-1H-5,8a-methylenechalcogenide-7-yl) ethyl ketone); methyl cinnamate (methyl 3-phenylprop-2-enoate); methyl tantalize (2-ethoxy-4-(methoxymethyl)phenol); methyl dihydroisojasmonate (methyl 2-hexyl-3-oxocyclopentane-1-carboxylate); methyl heptenone (6-methylhept-5-en-2-one); methyl lactone (8-methyl-1-oxaspiro[4.5]dec-2-one); methyl nonyl ketone (undecane-2-one); methyl octynecarboxylate (non-2-ynyl acid) Methyl ester); 6,6-dimethoxy-2,5,5-trimethylhex-2-ene; methyl salicylate (methyl 2-hydroxybenzoate); muscarne ((Z)-3-methylcyclopentadecano-5-enone); citric acid aldehyde (4-(4-methylpent-3-en-1-yl)cyclohex-3-encarbaldehyde); myrcene (7-methyl-3-methyleneoct-1,6-diene); MYSTIKAL (2-methylundecanoic acid); citric acid ketone (2-(2-(4-methylcyclohex-3-en-1-yl)propyl)cyclopentanone); neocitriol (2-methyl-6-methyleneoct-7-en-2-yl acetate); NEOCASPIRENE EXTRA (10-isopropyl-2,7-dimethyl-1-oxaspiro[4.5]dec-3,6-diene); Neofulliate ((E)-non-2-enoic acid methyl ester); NEROLIDYLE ((2Z)-3,7-dimethyloct-2,6-dien-1-ol); Nerolidol ((Z)-3,7,11-trimethyldodec-1,6,10-trien-3-ol); NEROLIDYLE (acetic acid (Z)-3,7,11-trimethyldodec-1,6,10-trien-3-yl ester); 2-ethoxynaphthalene ether crystals; Neonerol (1-(3-methylbenzofuran-2-yl)acetone); Nerolidol acetate ((Z)-3,7-dimethyloct-2,6-dien-1-yl ester); NIRVANOLIDE ((E)-1 3-Methyloxetane-10-en-2-one; nonadienal ((2E,6Z)-non-2,6-dienal); 2,6-nonadienol ((2Z,6E)-2,6-nonadien-1-ol); nonadienol (6,8-dimethylnon-2-ol); 5-pentyloxetane-2-one; cis-6-nonenal ((Z)-non-6-enal); cis-6-nonenol ((Z)-non-6-en-1-ol); 2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethyl acetate; NYMPHEAL (3-(4-(2-methylpropyl)-2-methylphenyl)propanal); 6-propyltetrahydro-2H-pyran-2-one; methylhexyl ketone (oct-2-one);Sweet orange crystals (1-(2-naphthyl)-acetone); Iris ketone (4-(tert-amyl)cyclohexanone); Ethyl phenethyl methyl ether ((2-methoxyethyl)benzene); p-tert-butylcyclohexyl acetate (4-(tert-butyl)cyclohexyl acetate); Fruit amide (2-ethyl-N-methyl-N-(m-tolyl)butyramide); Prunal (5-heptyldihydrofuran-2(3H)-one); Geraniol (2-methyl-4-methylene-6-phenyltetrahydro-2H-pyran); Tetrahydrogeraniol (3,7-dimethyloctyl-1-ol); Paeonyl nitrile (2-cyclohexene-2-phenylacetonitrile); PETALIA (2-cyclohexene-2-(o-tolyl)acetonitrile); Pharaohone (2-cyclohexylheptyl-1,6-dien-3-one) ); phenoxyethyl isobutyrate (2-methylpropionic acid 2-(phenoxy)ethyl ester); phenylacetaldehyde (2-phenyl-acetaldehyde); phenylethyl acetate (2-phenylethyl acetate); phenylethanol (2-phenylethanol); phenylethyl isobutyrate (2-methylpropionic acid 2-phenylethyl ester); phenylethylphenyl acetate (2-phenylacetic acid 2-phenylethyl ester); phenylpropanol (3-phenylprop-1-ol); methyl-pinene (2,6,6-trimethylbicyclo[3.1.1]hept-2-ene); ethyl-pinene (6,6-dimethyl-2-methylenebicyclo[3.1.1]heptane); pine acetaldehyde (3-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)propanol); neorose ester (2,2-propionic acid 2-... -Dimethyl-2-phenylethyl ester); POMAROSE ((2E,5E)-5,6,7-trimethyloct-2,5-dien-4-one); POMELOL (2,4,7-trimethyl-6-octen-1-ol); Methylcitric acid B (1-methyl-4-(4-methylpent-3-en-1-yl)cyclohex-3-encarbaldehyde); Isopentenyl acetate (3-methylbut-2-en-1-yl acetate); Cocoaldehyde (5-pentyldihydrofuran-2(3H)-one); Sterculia oryzanol ((E)-2-ethyl-4-(2,2,3-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol); Raspberry ketone (4-(4-hydroxyphenyl)but-2-one); Cyclic ether (2,4-di-di-ethyl-2-ethyl-2-one); Methyl-4-phenyltetrahydrofuran; Crystalline rose (2,2,2-trichloro-1-phenylethyl acetate); 9-decenol (dec-9-en-1-ol); Rose ether (4-methyl-2-(2-methylprop-1-en-1-yl)tetrahydro-2H-pyran); Rose ether CO (4-methyl-2-(2-methylprop-1-en-1-yl)tetrahydro-2H-pyran); ROSYFOLIA (1-methyl-2-(5-methylhex-4-en-2-yl)cyclopropylmethanol); Aromatic rose ether (4-methyl-2-phenyl-3,6-dihydro-2H-pyran); Indene (2,3,3-trimethyl-1-indanone); Crocinaldehyde (2,6,6-trimethylcyclohexyl-1,3-dienal);Sandalwood (3-methyl-5-(2,2,3-trimethylcyclopentan-3-en-1-yl)pentan-2-ol); Scentaurus Clean ((Z)-2-acetyl-4-methyltridecano-2-enoic acid ethyl ester); Scentaurus Juicy (4-(dodecylthio)-4-methylpentan-2-one); White Musk (cyclohexanecarboxylic acid 2-(1-(3,3-dimethylcyclohexyl)ethoxy)-2-methylpropyl ester); Cyclohexadecanolide (cyclopentadecanone, hexadecanolide); Silver aldehyde (2-methyl-3-[4-(2-methylpropyl)phenyl]propanal); Spirocyclogone (1-(spiro[4,5]dec-6-en-7-yl)pentan-4-en-1-one); Olivetrine ((E)-5-methylhept-3-one oxime); Styrax acetate (1-phenylethyl acetate); SUPER MUGUET ((E)-6-ethyl-3-methyloct-6-en-1-ol); Yucca musk ((E)-2-((3,5-dimethylhex-3-en-2-yl)oxy)-2-methylpropyl ester); methyl-4-propane (1-methyl-4-propane-2-ylcyclohex-1,3-diene); propyl-4-propane-2-ylcyclohex-1,4-diene; terpineol (2-(4-methylcyclohex-3-en-1-yl)propane-2-ol); methyl-4-propane (2-(4-) Methyl-1-cyclohexyl-3-enyl)prop-2-ol; terpineol (2-(4-methylcyclohexyl-3-en-1-yl)prop-2-ol); terpinene (1-methyl-4-(prop-2-ethylene)cyclohexyl-1-ene); terpineol acetate (2-(4-methyl-1-cyclohexyl-3-enyl)prop-2-yl ester); tetrahydrolinalool (3,7-dimethyloct-3-ol); tetrahydromyrcenol (2,6-dimethyloct-2-ol); Tibetan musk (oxacyclohexadecane-2-one); thymol (2-iso... Propyl-5-methylphenol); Cyclopropyl anisole (1-(cyclopropylmethyl)-4-methoxybenzene); Tricyclic terpene aldehyde (2,4-dimethylcyclohexyl-3-encarbaldehyde); Tridecene-2-onitrile ((E)-tridecene-2-encarbaldehyde); Neo-private aldehyde (3-phenylbutanal); Neo-jasmine aldehyde (3-(benzo[d][1,3]dioxacyclopenten-5-yl)-2-methylpropanal); Neo-jasmine aldehyde (3-(benzo[d][1,3]dioxacyclopenten-5-yl)-2-methylpropanal); Undecanetriol Alkenes ((3E,5Z)-undec-1,3,5-triene); Methyldecenol ((E)-4-methyldec-3-en-5-ol); Vanillin (4-hydroxy-3-methoxybenzaldehyde); Vanillone (2,2,5-trimethyl-5-pentylcyclopentanone); Cyclohexadecenone ((Z)-cyclohexadec-5-enone); Iononitrile ((2E,6Z)-nonano-2,6-dienonitrile); Diethylnaphthalene methyl ether (2-methoxynaphthalene); ZINARINE (2-(2,4-dimethylcyclohexyl)pyridine);BOIS CEDRE ESSCHINE; EUCALYPTUS GLOBULUS ESS CHINA; GALBANUM ESS; GIROFLE FEUILLES ESS RECT MADAGASCAR; LAVANDIN GROSSO OIL FRANCE ORPUR; MANDARIN OIL WASHED COSMOS; ORANGE TERPENES; PATCHOULI ESS INDONESIE; and YLANG ECO ESSENCE.

[0049] These flavoring ingredients are particularly well-suited for obtaining stable and high-performance microcapsules due to their favorable lipophilicity and olfactory properties.

[0050] In a particularly preferred embodiment of the invention, more than 75 wt.%, preferably more than 80 wt.%, even more than 85 wt.%, even more than 90 wt.%, and still more than 95 wt.%, of the fragrance component is biodegradable and selected from acetyl isoeugenol (acetic acid (E)-2-methoxy-4-(prop-1-en-1-yl)phenyl ester); adocal (2,6,10-trimethylundec-9-enal); AGRUMEX (acetic acid 2-(tert-butyl)cyclohexyl ester); C10 decanal (decanal); C11 undecenal (undec-10-enal); C110 undecal (undecal); C12 lauraldehyde (dodecanal); C12 MNA aldehyde (2-methylundecal); C8 octanal (octanal); and taurenal (3-(4-isopropylphenyl)-2-methylpropanal). ; ISOC11 aldehyde ((E)-undec-9-enal); allyl pentyl glycolate (2-(3-methylbutoxy)acetic acid prop-2-enyl ester); allyl cyclohexylpropionate (3-cyclohexylpropionate prop-2-enyl ester); allyl heptanate (heptanate prop-2-enyl ester); asterolone ((Z)-oxacycloheptadec-10-en-2-one); ambergris furan ((3aR,5aS,9aS,9bR)- 3a,6,6,9a-Tetramethyl-2,4,5,5a,7,8,9,9b-octahydro-1H-benzo[e][1]benzofuran); Amyl salicylate (2-hydroxybenzoic acid pentyl ester); anisaldehyde p-cresol (4-methoxybenzaldehyde); benzyl acetate (benzyl acetate ester); benzyl salicylate (2-hydroxybenzoic acid pentyl ester); Borneol acetate (acetic acid (2S,4S)-1,7,7-trimethylbicyclo[2.2]).1] Hept-2-yl ester); carvacrol (5-isopropyl-2-methylphenol); cypermethrin ((1S,8aR)-1,4,4,6-tetramethyl-2,3,3a,4,5,8-hexahydro-1H-5,8a-methylenechalcogenide); cypermethrin acetate ((1S,6R,8aR)-1,4,4,6-tetramethyloctahydro-1H-5,8a-methylenechalcogenide-6-yl ester); cypermethrin methyl ether ((1R,6S,8aS)-6-methoxy-1,4,4,6-tetramethyloctahydro-1H-5,8a-methylenechalcogenide); citral ((E)-3,7-dimethyloctyl-2,6-dienal); citronellol (3,7-dimethyloctyl) -6-en-1-ol); Citronellol acetate (3,7-dimethyloctyl-6-en-1-yl acetate); Celadon musk ((Z)-3-methylcyclotetradec-5-enone); p-cresol methyl ether (1-methoxy-4-methylbenzene); Cyclohexylethyl acetate (2-cyclohexylethyl acetate); Cyclohexyl salicylate (2-hydroxybenzoic acid cyclohexyl ester); Tufonone ((E)-1-(2,6,6-trimethylcyclohex-1,3-dien-1-yl)but-2-en-1-one); Alpha-tufonone ((E)-1-(2,6,6-trimethylcyclohex-2-en-1-yl)but-2-en-1-one); Propyldecyl lactone (5-hexyloxacyclopentan-2-one); trans Formula-4-decenal ((E)-dec-4-enal); dihydromyrcenol (2,6-dimethyloct-7-en-2-ol); diphenyl ether (oxydiphenyl); dihydroanisole (1-methoxy-4-propylbenzene); dihydrojasmone (3-methyl-2-pentylcyclopentanone); dimethyl anthranol (2-(methylamino)benzoate); dimethyl benzyl acetate (2-methyl-1-phenylprop-2-yl acetate); dimethyl benzyl butyrate (2-methyl-1-phenylprop-2-yl butyrate); dimethyl heptanol (2,6-dimethylheptanol); butyl dodecyl lactone (6-heptyltetrahydro-2H-pyran-2-one); propyl dodecyl lactone ( 5-Octooxacyclopentan-2-one); dodecenoal ((E)-dodeceno-2-one); ebony alcohol ((E)-3-methyl-5-(2,2,3-trimethylcyclopent-3-en-1-yl)pent-4-en-2-ol); ethyl hexanoate (ethyl hexanoate); ethyl methyl-2-butanoate (ethyl 2-methylbutanoate); ethyl maltol (2-ethyl-3-hydroxy-4H-pyran-4-one); ethyl heptanoate (ethyl heptanoate); ethyl vanillin (3-ethoxy-4-hydroxybenzaldehyde); ethylene brassinolate (1,4-dioxane-5,17-dione); eucalyptol ((1s,4s)-1,3,3-trimethyl-2-oxabicyclo[2.2]).2] Octane); Eugenol (4-allyl-2-methoxyphenol); Synthetic oakmoss (methyl 2,4-dihydroxy-3,6-dimethylbenzoate); FIXAMBRENE (3a,6,6,9a-tetramethyldodecano[2,1-b]furan); Anthocyanin (3-(3-isopropylphenyl)butanal); FLORIDILE ((E)-undec-9-enonitrile); Grupone (1-(5,5-dimethylcyclohexyl-1-en-1-yl)pent-4-en-1-one); Styrax acetate (1-phenylethyl acetate); Geraniol ((E)- 3,7-Dimethyloctyl-2,6-dien-1-ol); Geraniol acetate ((E)-3,7-dimethyloctyl-2,6-dien-1-yl ester); Cyclopentadene lactone ((E)-oxacyclohexadecano-12-en-2-one); Methyl dihydrojasmonate (3-oxo-2-pentylcyclopentane methyl acetate); trans-2-hexenal ((E)-hex-2-enal); cis-3-hexenol ((Z)-hex-3-en-1-ol); cis-3-hexenyl acetate ((Z)-hex-3-en-1-yl ester); cis-3-hexenyl salicylate ( 2-Hydroxybenzoic acid (Z)-hex-3-en-1-yl ester; hexyl acetate (hexyl acetate); indolene solution (8,8-di(1H-indole-3-yl)-2,6-dimethyloct-2-ol); ethyl ionone ((E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one); angelone ((E)-3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one); methyl ionone ((E)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one) But-3-en-2-one); isoamyl acetate (3-methylbutyl acetate); isoamyl butyrate (3-methylbutyl butyrate); isoeugenol ((E)-2-methoxy-4-(prop-1-en-1-yl)phenol); isojasmone B11 (2-hexylcyclopent-2-en-1-one); isomethyl ionone ((E)-3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one); jasmone (3-butyl-5-methyltetrahydro-2H-pyran-4-yl ester); lactone (8-isopropyl-1-oxaspiro[4].5] Dec-2-one); Citrile ((2E,6Z)-3,7-dimethylnon-2,6-dienone); Linalool (3,7-dimethyloct-1,6-dien-3-ol); Linalool oxide (2-(5-methyl-5-vinyltetrahydrofuran-2-yl)prop-2-ol); Linalyl acetate (3,7-dimethyloct-1,6-dien-3-yl acetate); Matricariacetin (ethyl 2-methylvalerate); Lily of the valley alcohol ((4-isopropylcyclohexyl)methanol); Roshol (3-methyl-5-phenylpentan-1-ol); Cucurbitaldehyde (2,6-dimethylhept-5-enal); Mercapto-8-menthane-3 - Ketone (Mercapto-p-menthane-3-one); Methyl anthranilate (Methyl 2-aminobenzoate); Methyl benzoate (Methyl benzoate); Methyl tantalize (2-ethoxy-4-(methoxymethyl)phenol); Methyl heptenone (6-methylhept-5-en-2-one); Methyl lactone (8-methyl-1-oxaspiro[4.5]dec-2-one); Methyl octyne carboxylate (Methyl non-2-ynyl ester); Methyl salicylate (Methyl 2-hydroxybenzoate); fentanyl ketone (2-(2-(4-methylcyclohexyl-3-en-1-yl)propyl)cyclopentanone); Neofulliate ((E)-non-2-enoate methyl ester); NERO LEX ((2Z)-3,7-dimethyloct-2,6-dien-1-ol); nerolidol ((Z)-3,7,11-trimethyldodecano-1,6,10-trien-3-ol); ethylnaphthalene ether crystals (2-ethoxynaphthalene); neonerol (1-(3-methylbenzofuran-2-yl)acetone); nerolithate ((Z)-3,7-dimethyloct-2,6-dien-1-yl acetate); nonadienal ((2E,6Z)-non-2,6-dienal); cis-6-nonenal ((Z)-non-6-enal); cis-6-nonenol ((Z)-non-6-en-1-ol); N YMPHEAL (3-(4-(2-methylpropyl)-2-methylphenyl)propanal); octyl lactone (6-propyltetrahydro-2H-pyran-2-one); sweet orange crystal (1-(2-naphthyl)-acetone); p-tert-butylcyclohexyl acetate (4-(tert-butyl)cyclohexyl acetate); peach aldehyde (5-heptyldihydrofuran-2(3H)-one); tetrahydrogeraniol (3,7-dimethyloctyl-1-ol); phenylethyl acetate (2-phenylethyl acetate); methyl-pinene (2,6,6-trimethylbicyclo[3.1.1]hept-2-ene); ethyl-pinene (6,6-dimethyl-2-methylenebicyclo[3.1.1]hept-2-ene).1] Heptane); POMAROSE ((2E,5E)-5,6,7-trimethyloct-2,5-dien-4-one); POMELOL FF (2,4,7-trimethyl-6-octen-1-ol); isopentenyl acetate (3-methylbut-2-en-1-yl acetate); coconut aldehyde (5-pentyldihydrofuran-2(3H)-one); raspberry ketone (4-(4-hydroxyphenyl)but-2-one); 9-decenol (dec-9-en-1-ol); rose ether CO (4-methyl-2-(2-methylprop-1-en-1-yl)tetrahydro-2H-pyran); aromatic rose ether (4-methyl-2-phenyl-3,6-dihydro-2H-pyran); saffron aldehyde (2,6,6-trimethylcyclohexane-1,3-dien-carboxaldehyde); SCENTAURUS JUICY (4-(dodecylthio)-4-methylpentan-2-one); silver aldehyde (2-methyl-3-[4-(2-methylpropyl)phenyl]propanal); styrax acetate (1-phenylethyl acetate); yucca musk (cyclohexanecarboxylic acid (E)-2-((3,5-dimethylhex-3-en-2-yl)oxy)-2-methylpropyl ester); terpinene (1-methyl-4-prop-2-ylcyclohex-1,4-diene); terpineol (2-(4-methylcyclohex-3-en-1-yl)prop-2-ol); terpinene (1-... -Methyl-4-(prop-2-ethylene)cyclohexyl-1-ene); Tetrahydrolinalool (3,7-dimethyloctyl-3-ol); Cyclopropyl anisole (1-(cyclopropylmethyl)-4-methoxybenzene); Tridecenoen-2-onitrile ((E)-tridecenoen-2-ene acrylonitrile); Neoprivetaldehyde (3-phenylbutanal); Neojasmine aldehyde (3-(benzo[d][1,3]dioxacyclopenten-5-yl)-2-methylpropanal); Methyldecenol ((E)-4-methyldec-3-en-5-ol); Diethylnaphthalene methyl ether (2-methoxynaphthalene); BOIS The ingredients include: cephalosporin oil; eucalyptus globulus eschina oil; galbanum eschina oil; girofle feuilles eschina recta magazine oil; lavandin grosso oil france orpur; mandarin oil washed cosmos; orange terpenes; patchouli esindonesie; and ylang-ylang oil. These ingredients offer the advantage of providing microcapsules, where both the shell and core are biodegradable.

[0051] In the context of this invention, a "biodegradable ingredient" is an ingredient that meets the criteria of "inherently biodegradable" and / or "easily biodegradable" in at least one OECD biodegradation study. To avoid any ambiguity, this means that if an ingredient passes one test but fails one or more other tests, the result of one test overrides the results of the others.

[0052] To assess the pass criterion of "ease of biodegradation", biodegradation studies may be selected from OECD Method 301C, OECD Method 301D, OECD Method 301F and OECD Method 310. These methods are suitable for volatile materials.

[0053] OECD Methods 301C, 301D, and 301F are described in the OECD Guidelines for the Testing of Chemicals, Section 3, Test No. 301: Ready Biodegradability (adopted: July 17, 1992; https: / / doi.org / 10.1787 / 9789264070349-en).

[0054] OECD Method 310 is described in OECD Guidelines for the Testing of Chemicals, Section 3, Test No. 310: Ready Biodegradability - CO2 in sealed vessels (Headspace Test) (Adopted: 23 March 2006; Revised: 26 September 2014; https: / / doi.org / 10.1787 / 9789264016316-en).

[0055] In one particular aspect of the invention, the pass criterion for "ease of biodegradability" is assessed according to OECD Method 301F, which involves manometric respirometry. In this method, the pass level for "ease of biodegradability" is defined as achieving 60% of the basal oxygen demand (BOD) and / or chemical oxygen demand (COD). This pass value must be achieved within a 10-day window within a 28-day testing period. The 10-day window begins when the degree of biodegradation reaches 10% of the BOD and / or COD and must end before day 28 of the test.

[0056] Based on the positive results in the readily available biodegradability tests, it can be presumed that the chemicals will undergo rapid and eventual biodegradation in the environment (Introduction to the OECD Guidelines for the Testing of Chemicals, Section 3, Part 1: Principles and Strategies Related to the Testing of Degradation of Organic Chemicals; adopted: July 2003).

[0057] To assess the pass criteria for "inherently biodegradable," biodegradation studies can be conducted using OECD Method 302C, but OECD Method 301F can also be used, although they have different pass criteria. These methods are also suitable for volatile materials.

[0058] OECD Method 302C is described in OECD Guidelines for the Testing of Chemicals, Section 3, Test No. 302C: Inherent Biodegradability: Modified MITI Test (II) (Adopted: 12 May 1981; Revised: 8 September 2009; https: / / doi.org / 10.1787 / 9789264070400-en).

[0059] In one particular aspect of the invention, the pass criterion for "inherent biodegradability" is assessed using OECD method 302C. In this method, the pass level for "inherent biodegradability" is 70% of the pyrochemical oxygen demand. There is no time limit for reaching this level.

[0060] A biodegradation rate higher than 70% can be considered as evidence of inherent ultimate biodegradability (OECD Guidelines for the Testing of Chemicals, Section 3, Part 1: Principles and Strategies Related to the Testing of Degradation of Organic Chemicals; adopted: July 2003).

[0061] If OECD Method 301F is used to assess the pass criterion for “inherently biodegradable,” the pass level is 60% of the theoretical oxygen demand and / or chemical oxygen demand. This pass value can be achieved after a 28-day testing period, which is typically extended to 60 days. The 10-day window is not applicable.

[0062] In the context of this invention, if the ingredient is an essential oil, it is considered a "biodegradable ingredient" if all its components present at a level of ≥1 wt.% fall within the definitions of "inherently biodegradable" and / or "easily biodegradable" as defined above. However, essential oils can also undergo the above-described biodegradation tests.

[0063] The core composition may also contain at least one fragrance precursor, i.e., a material capable of releasing fragrance components by stimulating means such as temperature changes, the presence of oxidants, enzymatic action, or light. Such fragrance precursors are well known in the art.

[0064] The core composition may also contain at least one functional cosmetic ingredient. The functional cosmetic ingredient in the composition used for encapsulation is preferably hydrophobic.

[0065] Particularly useful functional cosmetic ingredients can be selected from emollients, smoothing ingredients, hydrating ingredients, soothing and relaxing ingredients, decorative ingredients, deodorants, anti-aging ingredients, cell regeneration ingredients, drainage ingredients, reshaping ingredients, skin smoothing ingredients, preservatives, antioxidants, antibacterial or bacteriostatic ingredients, cleansing ingredients, lubricating ingredients, structuring ingredients, hair conditioning ingredients, whitening ingredients, texture ingredients, softening ingredients, anti-dandruff ingredients, and exfoliating ingredients.

[0066] Particularly useful functional cosmetic ingredients include, but are not limited to, hydrophobic polymers such as alkyl dimethylsiloxane, polymethyl silsesquioxane, polyethylene, polyisobutylene, styrene-ethylene-styrene, and styrene-butene-styrene block copolymers; mineral oils such as hydrogenated isoparaffins, silicone oils, etc.; plant oils such as argan oil, jojoba oil, aloe vera oil, etc.; fatty acids and fatty alcohols and their esters; glycolipids; phospholipids; sphingolipids such as ceramides; sterols and steroids; terpenes, sesquiterpenes, triterpenes and their derivatives; essential oils such as arnica oil, artemisia oil, bark oil, birch leaf oil, calendula oil, cinnamon oil, echinacea oil, eucalyptus oil, ginseng oil, jujube oil, sunflower oil, jasmine oil, mixed lavender oil, lotus seed oil, perilla oil, rosemary oil, sandalwood oil, tea tree oil, thyme oil, valerian oil, wormwood oil, ylang-ylang oil, and yucca oil.

[0067] In particular, the at least one functional cosmetic ingredient may be selected from sandalwood oil, such as sandalwood kernel oil; panthenol triacetate; tocopheryl acetate; tocopherol; naringin; ethyl linoleate; farnesyl acetate; farnesol; citronellol methyl crotonate; and ceramide-2 (1-stearoyl-C18-sphingosine, CAS-No: 100403-19-8).

[0068] To provide an optimal balance between stability, deposition on substrate, and performance, the median diameter (Dv(50)) of the microcapsules can be from 1 to 150 μm, preferably from 5 to 100 μm, and even more preferably from 8 to 25 μm. Microcapsules with a diameter less than 5 μm exhibit a larger surface area to volume ratio and are therefore more prone to leaching, while microcapsules that are too large may not provide significant benefits due to the decreasing number of microcapsules with increasing diameter. Furthermore, large microcapsules may be visible in the product or leave visible stains on the substrate.

[0069] One particular aspect of the invention relates to a composition comprising at least one core-shell microcapsule. The at least one core-shell microcapsule comprises a core and a shell surrounding the core, the core comprising at least one beneficial agent. The shell comprises first and second polyelectrolytes forming a composite cohesive layer. The microcapsule comprises at least one crosslinking agent that crosslinks the first and / or second polyelectrolytes. The crosslinking agent is derived from a dialdehyde selected from 1,3-phenylenedialdehyde, 1,3-cyclohexanedialdehyde, cyclopentane-1,3-dialdehyde, furan-2,5-dialdehyde, and 1,4-dicarboxypiperazine. Preferably, the crosslinking agent is derived from 1,3-phenylenedialdehyde. The first polyelectrolyte is a protein selected from soy protein, pea protein, rice protein, and hemp protein. Preferably, the first polyelectrolyte is soy protein.

[0070] In a second aspect, the present invention provides a method for preparing encapsulation compositions, particularly the compositions described above, the method comprising the following steps:

[0071] a) Provide a core composition comprising an interface enabler or a material from which an interface enabler can be derived;

[0072] b) Provide an aqueous phase comprising the first and second polyelectrolytes;

[0073] c) Emulsify the core composition provided in step a) into the aqueous phase provided in step b) to obtain core composition droplets dispersed in the aqueous phase, the core composition droplets having a median volume diameter of 1 to 100 μm, preferably 5 to 75 μm, more preferably 8 to 60 μm, and even more preferably 7 to 20 μm.

[0074] d) Lower the pH until the coagulation pH is reached, thereby forming a slurry of core-shell microcapsules;

[0075] e) Optionally: add a crosslinking agent (or additional crosslinking agent if applicable), and keep the slurry under stirring to obtain a slurry of crosslinked microcapsules.

[0076] Regarding step a), the mixing of the core components can be carried out at room temperature and with stirring.

[0077] Regarding step b), the aqueous phase can be obtained at a pH of 5 to 13, preferably 7 to 13, more preferably 9 to 12.5, and even more preferably 11 to 12. The polyelectrolyte dissolves better under such alkaline conditions. This step is preferably carried out at a temperature of 30°C or higher, but preferably below 60°C, because proteins subjected to high temperatures and high pH may tend to hydrolyze. Optimally, the dissolution temperature is 45 ± 5°C.

[0078] Therefore, in a preferred embodiment of the invention, the protein, preferably a protein derived from a strictly vegan source, is dissolved in the aqueous phase at a temperature of 45±5°C, preferably at a pH of 5 to 13, more preferably 7 to 13, still more preferably 9 to 12.5, and even still more preferably 11 to 12.

[0079] Furthermore, in a preferred embodiment of the invention, the polysaccharide is dissolved in the aqueous phase at a temperature of 45±5°C, preferably at a pH of 5 to 13, more preferably 7 to 13, still more preferably 9 to 12.5, and even still more preferably 11 to 12.

[0080] Regarding step c), the emulsion can be obtained at a temperature of 30 to 60°C, preferably 30 to 40°C. Within this temperature range, the polymer-polymer complex is expected to remain sufficiently weak to allow for easy disruption of the core / water interface and subsequent disruption of the core droplets.

[0081] At the end of the complex coagulation process, the addition of a water-soluble or water-dispersible crosslinking agent (and, if applicable, additional crosslinking agents) can form a covalently crosslinked network structure around the microcapsule core, thereby forming a crosslinked encapsulation shell. Crosslinking typically involves the free amino groups of proteins, which are the most reactive and available groups in the complex coagulated layer. Suitable crosslinking agents include 1,3-malondialdehyde, 1,4-butanedialdehyde, 1,5-glutaraldehyde or 1,6-hexanedialdehyde (glutaraldehyde), succinaldehyde, glyoxal, oxaloyl trimer, resorcinol, polyfunctional isocyanates, dianhydrides, trihydrides and polyanhydrides, N-hydroxysuccinimide, diesterimide, carbodiimide and dicarboxylic acid disuccinimide.

[0082] Alternatively, protein-protein cross-linking can be advantageously promoted by adding transglutaminase to the slurry. Transglutaminase catalyzes the cross-linking between two protein (or peptide) fragments by forming a covalent bond between a glutamine residue in one fragment and a lysine residue in a second fragment. If transglutaminase is used for protein-protein cross-linking, proteins with higher amounts of the amino acids glutamine and lysine are preferred. Such proteins are, for example, globular proteins from nuts and legumes, particularly soy protein.

[0083] In a preferred embodiment of the invention, in step e), a crosslinking agent (or additional crosslinking agent, if applicable) is added at a temperature of 10°C to 50°C, more particularly 15°C to 40°C, and the reaction is allowed to proceed for 1 to 20 hours, preferably 5 to 15 hours, for example overnight, and then the slurry is cooled at room temperature.

[0084] In a particular embodiment of the invention, the cross-linking agent (or, if applicable, the additional cross-linking agent) is selected from glutaraldehyde and transglutaminase.

[0085] Furthermore, the slurry of microcapsules obtained in step e) can be dried by any method known in the art, such as oven drying, drum drying, freeze drying, spray drying, or fluidized bed drying. Prior to the drying process, the microcapsules can be separated from the slurry by flotation.

[0086] Preferably, dehydration is performed using spray drying or multi-stage spray drying. Typically, spray drying is performed by spraying the slurry obtained in step d) or e) into a heated chamber using a nozzle, preferably a two-fluid nozzle, or a rotary atomizer or rotating disk. Typically, the slurry can be pumped and atomized with a co-current airflow through a nozzle or rotating disk in a spray drying apparatus for drying. Typical inlet temperatures can be set between 160 and 220°C, and outlet temperatures can be set between 60 and 100°C. Dried particles containing encapsulated microcapsules and with a particle size of about 10 to about 120 μm can then be collected at the dryer outlet. This drying method is well known in the art. In a multi-stage dryer, the spray-dried particles are further agglomerated to obtain larger particles with a particle size of 100 to 250 μm.

[0087] In an alternative embodiment of the invention, the slurry obtained in step d) or e) can be sprayed in a fluidized bed dryer (e.g., a Wurster coating apparatus) onto a fluidized carrier material having a predetermined average particle size to obtain carrier particles coated with a microcapsule drying layer.

[0088] In a further alternative embodiment of the invention, the microcapsules contained in the slurry obtained in step d) or e) can be granulated or agglomerated in a fluidized bed dryer to obtain particles with a particle size of 150 to 400 μm or more.

[0089] In other alternative embodiments of the invention, the microcapsules may be separated from the slurry by flotation or filtration and dried in a fluidized bed dryer at a temperature of 60 to 150°C, more particularly 80 to 120°C, to obtain particles having approximately the same size as the microcapsules contained in the slurry obtained in step d) or e).

[0090] The method of the present invention may further include a dilution step, wherein the dried particles are mixed with at least one carrier material selected from urea, sodium chloride, sodium sulfate, sodium acetate, zeolite, sodium carbonate, sodium bicarbonate, clay, talc, calcium carbonate, magnesium sulfate, gypsum, calcium sulfate, magnesium oxide, zinc oxide, titanium dioxide, calcium chloride, potassium chloride, magnesium chloride, zinc chloride, sugars, polyethylene glycol, polyvinylpyrrolidone, citric acid or any water-soluble solid acid, fatty alcohol, fatty acid.

[0091] The mixing of dried microcapsules with at least one carrier material can be carried out by any method known in the art, including convection blending, blade blending, fluidized bed blending, tumbling mixing, and vortex blending. In a third aspect, the present invention provides encapsulated compositions obtainable by the methods described above.

[0092] In a fourth aspect, the present invention provides the use of interface enablers in obtaining encapsulated compositions, particularly encapsulated compositions as described above.

[0093] Furthermore, the present invention provides consumer products comprising the encapsulated composition as described above, wherein the consumer products are preferably fabric care products, home care products, or personal care products.

[0094] The encapsulated compositions of the present invention can be used to flavor all forms of consumer products, including laundry care detergents, laundry care conditioners, fabric fresheners, personal care cleaning compositions (e.g., shampoos, shower gels, and body washes), liquid soaps, soap bars, personal care conditioning compositions (e.g., conditioners), body washes, deodorant compositions, antiperspirant compositions, and household care compositions (e.g., hard surface cleaners and heavy-duty detergents).

[0095] The consumer products of the present invention can be used to treat substrates such as fabrics, skin, hair, living and non-living surfaces, and hard surfaces, wherein the effects of treating the substrate include washing, cleaning, softening, conditioning, finishing, fragrance and / or deodorizing the substrate.

[0096] In one aspect of the invention, the consumer product comprises the composition as described above, preferably at a level of 0.005 to 5 wt.-%, more preferably 0.01 to 1 wt.-%, and still more preferably 0.02 to 0.5 wt.-%.

[0097] In many cases, the consumer products of the present invention contain surfactants, such as anionic surfactants, cationic surfactants, amphoteric surfactants, or nonionic surfactants.

[0098] The consumer products of the present invention may contain acids or bases, or substances that provide acidity or alkalinity, also referred to as acidity sources or alkalinity sources.

[0099] The consumer products of the present invention may contain synergistic agents for reducing water hardness, such as phosphates, polyphosphates, polycarboxylate, sodium citrate, sodium carbonate, sodium silicate, and sodium aluminosilicate (zeolite).

[0100] In many cases, the consumer products of the present invention are liquids and may contain additional additives, such as solvents, fillers, structure modifiers such as thickeners and rheology modifiers, distribution modifiers, anti-redeposition agents, preservatives, deodorants, cosmetic ingredients, and surface enhancers.

[0101] The microcapsule-containing consumer products of the present invention may contain at least one solvent selected from water-soluble solvents, or water-insoluble or partially water-soluble solvents.

[0102] Consumer products containing the microcapsules of the present invention may contain at least one structure modifier and / or colloidal stabilizer selected from rheology modifiers, thickeners, gelling agents, thixotropic agents, and dispersants.

[0103] The microcapsule-containing consumer products of the present invention may contain at least one siloxane selected from, but not limited to, dimethylsiloxane, poly(dimethylsiloxane-dimethylsiloxane), amino-siloxane, such as amino-terminated polydimethylsiloxane, trialkylammonium-siloxane salt, and ethoxylated siloxane.

[0104] The microcapsule-containing consumer products of the present invention may contain at least one cosmetic ingredient selected from, but not limited to, emollients, moisturizers, anti-wrinkle agents, exfoliants, sunscreens, dyes, pigments, talc, conditioning agents, hair styling agents, and anti-dandruff agents.

[0105] The microcapsule-containing consumer products of the present invention may contain at least one fabric reinforcing agent selected from, but not limited to, softeners, optical brighteners, and antistatic agents.

[0106] In a specific embodiment of the invention, the consumer product is a personal care deodorant or antiperspirant composition, which may be in the form of a sprayable composition or a composition that can be applied directly to the skin via a roller, stick, cream, or powder. The encapsulated composition of the invention may be incorporated into the deodorant or antiperspirant composition as a slurry of microcapsules obtained by the methods described above or in a dry form.

[0107] Sprayable deodorant and antiperspirant compositions may contain condensable propellant gases, such as isobutane; suspending agents, such as silica and hydrophobic bentonite; one or more solvents, such as water and ethanol; lipids, such as isopropyl myristate; surfactants; polyols, such as glycerin; antiperspirant compounds, such as aluminum chloride hydrate; deodorant compounds, such as zinc carbonate, cyclodextrin, and calcium, aluminum, magnesium, or zinc salts of unsaturated aliphatic hydroxycarboxylic acids, such as zinc ricinoleate; and fragrances.

[0108] The deodorant and antiperspirant roll-on composition may be in gel or liquid form and comprises a gelling agent, such as a sodium salt of fatty acid, such as sodium stearate, polyamide, and siloxane-based gelling agents; a suspending agent, such as hydrophobic bentonite; an emulsifier, such as fatty acid polyethylene glycol esters, such as stearyl alcohol polyether-2, stearyl alcohol polyether-4, stearyl alcohol polyether-6, stearyl alcohol polyether-7, stearyl alcohol polyether-10, stearyl alcohol polyether-11, stearyl alcohol polyether-13, stearyl alcohol polyether-15, stearyl alcohol polyether-20, and glyceryl esters and ethers; fatty alcohols, such as cetyl alcohol and stearyl alcohol; antiperspirant compounds, such as aluminum chloride hydrate, lipids, such as isopropyl myristate, and vegetable oils; fatty acids, such as stearic acid; alcohols and polyols, such as ethanol and glycerin; and water.

[0109] Deodorant sticks and creams may contain antiperspirant complexes such as aluminum and aluminum zirconium polychlorohydrate; waxy materials such as stearyl alcohol and cetyl alcohol, mixed with hydrogenated oils such as hydrogenated castor oil; emulsifiers such as glyceryl stearate; emollients such as cyclodimeticone; and powdered materials such as talc and starch.

[0110] In a fourth aspect, the present invention relates to the use of the encapsulated composition as described above in obtaining consumer products.

[0111] Other features and specific advantages of the invention will become apparent from the following embodiments.

[0112] Example 1: Preparation of microcapsules

[0113] In Example 1.1, the microcapsules of the present invention were prepared by performing the following steps:

[0114] a) The core composition was obtained by dissolving 0.25 g of isophthalaldehyde (1,3-phenylenedialdehyde) and 0.004 g of Solvent Yellow 98 fluorescent dye in 19.75 g of the fragrance composition;

[0115] b) Provide a first aqueous phase, which is prepared by dissolving 4.55 g of solid soybean protein isolate (Clarisoy 170, ex Arthur Daniel Midland Company) in 41.7 g of 0.43 wt.-% sodium hydroxide in a deionized aqueous solution (pH 11.5) at 45 °C and cooling the solution to room temperature;

[0116] c) A second aqueous phase is provided, which is prepared by dissolving 0.45 g of carboxymethyl cellulose in a deionized aqueous solution of 19.3 g of 0.6 wt.-% sodium hydroxide at 45 °C and cooling the solution to room temperature;

[0117] d) Provide a third aqueous phase, which consists of a deionized aqueous solution of sodium hydroxide at pH 11.5;

[0118] e) The first aqueous phase is heated to 35°C in a 400 ml reactor vessel by stirring with a paddle.

[0119] f) Add the second aqueous phase dropwise to the first aqueous phase through a dropping funnel while stirring, over a period of 15 minutes;

[0120] g) Rinse the dropping funnel with about 1g of the third aqueous phase and collect the rinsing water in the reactor;

[0121] h) Increase the stirring speed to 300 rpm and add the core composition dropwise through a dropping funnel over 24 minutes to obtain an emulsion;

[0122] i) Rinse the dropping funnel with about 1g of the third aqueous phase and collect the rinsing water in the reactor;

[0123] j) Reduce the stirring speed to 180 rpm and add the remaining third aqueous phase through a dropping funnel over 13 minutes, while keeping the emulsion obtained in step i) under stirring.

[0124] k) A 22.5 wt.% citric acid aqueous solution is continuously added to the emulsion obtained in step j) at a rate of 1.3 ml / h until a coagulation pH of 5.2 ± 0.2 is reached, thereby forming a slurry of core-shell microcapsules;

[0125] l) Slowly add 1.3 ml of a 25 wt.% glutaraldehyde aqueous solution;

[0126] m) The slurry formed in step l) is kept at 35°C with stirring for 60 minutes, and then the slurry is cooled to room temperature overnight (about 15 hours) to obtain the slurry of cross-linked microcapsules.

[0127] When the rate of weight change due to drying drops below 0.1 wt.-% / min, the solids content is taken as a percentage by weight of the initial slurry deposited on a thermal balance operating at 120°C. The ratio of the measured solids content to the theoretical solids content calculated based on the weight of the fragrance composition and encapsulating material used is taken as a measure of encapsulation efficiency, expressed as wt.-%.

[0128] Microcapsule size distribution was measured using a Beckman-Coulter LS 13 320 laser particle size analyzer.

[0129] The slurry contained no aggregates, had a solids content of 20.2 wt.-%, a median volume size Dv(50) of 9 μm, a median volume size Dv(90) of 15 μm, and an encapsulation efficiency of 95 wt.-%.

[0130] In Example 1.2, the microcapsules of the present invention were prepared by the same method as in Example 1.1, except that in step l), 0.4 g of transglutaminase (Activa TI, ex Ajinomoto) dissolved in 3.6 ml of deionized water was used instead of glutaraldehyde. In this case, in step m), the temperature of the slurry was raised to 50°C and maintained for 1 hour, then lowered to 35°C and maintained at the latter temperature overnight (about 16 to 17 hours), and then the slurry of the cross-linked microcapsules was cooled to room temperature.

[0131] The slurry contained no aggregates, had a solids content of 20.6 wt.-%, a median volume size Dv(50) of 6 μm, a median volume size Dv(90) of 10 μm, and an encapsulation efficiency of 96 wt.-%.

[0132] Example 2: Changes in enablers

[0133] In Examples 2.1 to 2.16, the microcapsules of the present invention were prepared by performing the steps described in 1.1 or 1.2, but using various enabling agents and enabling agent concentrations. Details of these experiments are reported in Table 1 for microcapsule samples crosslinked with glutaraldehyde, and in Table 2 for microcapsule samples crosslinked with transglutaminase, along with microcapsule size, encapsulation efficiency, and heptane-extractable oil. The percentage of enabling agent refers to the total weight of the core composition.

[0134] The determination of heptane-extractable oil was performed as follows: 1.5 g of slurry was extracted with 5.5 ml of heptane at 30-40 rpm for 2 hours by tumbling. The mixture was then centrifuged at 3150 rpm for 5 minutes. The upper heptane phase was siphoned off, and its VIS spectrum between 350 nm and 650 nm was recorded. Based on the linear calibration curve, the percentage of extracted oil was calculated according to the absorbance at 449 nm.

[0135] Table 1: Samples cross-linked with glutaraldehyde

[0136]

[0137]

[0138] 1 Larger capsules, ranging from 50 to 100 μm, also exist.

[0139] Table 2: Samples cross-linked with transglutaminase

[0140]

[0141] The results in Tables 1 and 2 show that microcapsules obtained in the presence of 0.25 wt.% or more of an enabler are better than those obtained without an enabler. At 0.5 wt.% or more, not only is the encapsulation efficiency of the microcapsules improved, but the size of the microcapsules is also within the preferred range.

[0142] The results also showed that the optimal conditions for cross-linking the microcapsules with glutaraldehyde and transglutaminase were met at an interfacial enabler concentration of 1.25 wt.-% (based on the total weight of the core composition). Under these specific conditions, there was no significant difference in the effect between the two cross-linking agents, as indicated by similar amounts of extractable oil in heptane determined in both cases.

[0143] Compared to the low encapsulation efficiency, the low level of heptane-extractable oil in sample 2.8 suggests that the microcapsules obtained using pimelic acid as an enabler have lower thermal stability than those obtained using phthalic acid as an enabler.

[0144] Example 3: Comparative Example

[0145] In Example 4.1, comparative microcapsules were prepared by performing the following steps:

[0146] a) Provide a 165g core composition consisting of medium-chain triglyceride Miglyol 812 (ex Oleo);

[0147] b) The first aqueous phase is provided by dissolving 16.5 g of type B fish gelatin in 148.5 g of deionized water at 40 °C;

[0148] c) A second aqueous phase is provided by dissolving 1.6 g of carboxymethyl cellulose in 77.9 g of deionized water at 40 °C;

[0149] d) The core composition was added to the first aqueous phase by stirring at 300 rpm using a paddle, and stirring was maintained for 30 minutes to provide an emulsion;

[0150] e) Add the second aqueous phase to the emulsion obtained in step d) with stirring;

[0151] f) Add 475g of deionized water preheated to 40°C while stirring.

[0152] g) The pH of the emulsion was adjusted to a coagulation pH of 5.2 ± 0.5 by using a 50 wt.-% citric acid solution, and the emulsion was cooled to 28 ± 1 °C at a rate of 1 °C / 5 min to form a slurry of core-shell microcapsules.

[0153] h) Cool the slurry formed in g) to a temperature of 20±5℃;

[0154] i) Add 0.26 g of glutaraldehyde and let the slurry stand overnight (about 15 hours) with stirring to provide a slurry for cross-linking core-shell microcapsules;

[0155] j) Separate the microcapsules obtained in step j) from the aqueous phase by flotation to obtain a cake of microcapsules;

[0156] k) Dry the cake obtained in step j) at about 80°C in a vacuum oven or at about 70°C in a fluidized bed dryer to obtain free-flowing so-called “blank” microcapsules containing medium-chain triglycerides as the core composition but without fragrance;

[0157] l) Transfer 56.8 g of blank microcapsules to a low-shear mixer, such as a belt mixer;

[0158] m) Add 5g of deionized water to the entire surface of the blank microcapsule;

[0159] n) Turn on the mixer at 60±5 rpm and keep mixing for 10-15 minutes until the mixture is homogeneous to obtain hydrated blank microcapsules;

[0160] o) Turn off the mixer and add 38.2 g of the flavor composition to the entire surface of the hydrated blank microcapsules obtained in step n);

[0161] p) Turn on the mixer at 60±5 rpm and keep mixing for 10-15 minutes;

[0162] q) Turn off the mixer, close the bed (lit) and allow the microcapsules to absorb the fragrance oil until a dry powder of the fragranced microcapsules is obtained, thus forming a dry powder of the fragranced microcapsules;

[0163] The size of the microcapsules is limited by sieving the powder obtained in step q) through a 150-micron sieve. The actual fragrance content of the microcapsules is 50 wt.% based on the total weight of the microcapsules.

[0164] Example 4: Olfactory assessment under the armpit

[0165] The microcapsule slurry obtained in Examples 1.1 and 3.1 was incorporated into a standard unfragranted deodorant roll-coated article, such that the fragrance level in the article was 0.1 wt.-% based on the total weight of the article. The article was then immersed for 2 days.

[0166] Olfactory assessments were conducted directly from the armpits by a group of untrained female assessors. Assessments were performed immediately after deodorant application, and then at 2, 6, and 10 hours through a cloth. At 10 hours, participants were asked to move their arms back and forth in a single motion and then rate the fragrance intensity, first through a cloth and then directly from the skin.

[0167] Based on a pre-determined random grouping, the sample is assigned to which arm (left or right), and evaluators are always required to evaluate their left armpit first.

[0168] Untrained evaluators used a 0-10 scale to assess the perceived intensity of spices. Evaluators were told that 0 = very weak and 10 = very strong.

[0169] Each sample was evaluated by 56 untrained female evaluators.

[0170] The data were analyzed using a paired-samples t-test, with the confidence level set at 95%. A separate paired t-test was performed for each time point. The results are reported in Table 3. When the same letter is displayed in the “Significance of Difference” column, there is no statistically significant difference between the relevant figures at a 95% confidence level.

[0171] Table 3: Scent intensity rating under the armpits

[0172]

[0173] As is evident from Table 3, at all stages of the evaluation process, the microcapsules of the present invention tend to have superior or at least comparable performance to the contrasting non-strictly vegetarian microcapsules.

[0174] Example 5: Olfactory Assessment on a Mat

[0175] The slurry of the microcapsules obtained in Examples 1.1 and 1.2 was incorporated into a standard unfragranted deodorant roll-coated article, such that the fragrance level in the article was 0.1 wt.-% based on the total weight of the article. The article was then immersed for 2 days.

[0176] 0.6g of each product was applied to a cotton pad using a pipette. A panel of 10 experts assessed the olfactory intensity of both fresh and samples applied 6 hours prior.

[0177] Each sample was evaluated for 6 hours before and after rubbing one part of the mat against another part of the mat. A first evaluation was performed to score the strength before friction, and a second evaluation was performed to score the strength after friction. Scores were given on a scale of 5 units (0 = no strength, 1 = very low, 2 = low, 3 = average, 4 = strong, and 5 = very strong). The results are reported in Table 4.

[0178] Table 4: Scent Intensity Rating on the Mat

[0179]

[0180] The results showed that the performance of microcapsules cross-linked with transglutaminase was comparable to that of microcapsules cross-linked with glutaraldehyde.

Claims

1. An encapsulated composition comprising at least one core-shell microcapsule, wherein the at least one core-shell microcapsule comprises a core and a shell surrounding the core, the core comprising at least one beneficial agent, wherein the core is composed of a liquid core composition, wherein the shell comprises first and second polyelectrolytes forming a composite cohesive layer, and wherein the microcapsule comprises at least one interface enabler, wherein the interface enabler is a diacid or a cyclic dialdehyde or said interface enabler is derived from a diacid or a cyclic dialdehyde; and additional crosslinking agents. The crosslinking agent, wherein the additional crosslinking agent is selected from 1,3-propanedialdehyde, 1,4-butanedialdehyde, 1,5-pentanedialdehyde, 1,6-hexanedialdehyde, succinaldehyde, glyoxal, oxaloyl trimer, resorcinol, polyfunctional isocyanates, dianhydrides, trihydrides, polyanhydrides, N-hydroxysuccinimide, diesterimide, carbodiimide, dicarboxylic acid disuccinimide, and transglutaminase, wherein the interface enabler refers to a substance having the ability to interact with at least one polyelectrolyte at the phase interface of the core composition to promote shell formation.

2. The encapsulated composition of claim 1, wherein the interface enabler is soluble in the core composition or derived from a material soluble in the core composition.

3. The encapsulated composition of claim 1, wherein the interface enabler is a crosslinking agent that crosslinks the first and / or second polyelectrolytes.

4. The encapsulated composition according to any one of claims 1 to 3, wherein the first polyelectrolyte is an amphoteric polyelectrolyte.

5. The encapsulated composition of claim 4, wherein the isoelectric point of the amphoteric polyelectrolyte is below pH 7.

6. The encapsulated composition of claim 1, wherein the solubility of the first and second polyelectrolytes in water is greater than 5 wt.% at pH 7 ± 0.5 and room temperature.

7. The encapsulated composition of claim 4, wherein the amphoteric polyelectrolyte is a protein.

8. The encapsulated composition of claim 4, wherein the amphoteric polyelectrolyte is a protein derived from a strict vegan source.

9. The encapsulated composition of claim 8, wherein the protein derived from a vegan source is selected from soy protein, pea protein, rice protein, and hemp protein.

10. The encapsulated composition of claim 7, comprising an aqueous solution of 5 wt.% of protein in nominal percentage, comprising less than 0.1 wt.% of insoluble material, wherein the total weight of the solution is considered.

11. The encapsulated composition of claim 1, wherein the second polyelectrolyte is a polysaccharide.

12. The encapsulated composition of claim 1, wherein the second polyelectrolyte is a polysaccharide containing a carboxylic acid group.

13. The encapsulated composition of claim 12, wherein the polysaccharide comprising a carboxylic acid group is selected from carboxymethyl cellulose, gum arabic, alginate, pectin, hyaluronic acid, xanthan gum, gellan gum, and their salts with monovalent alkali metals.

14. The encapsulated composition of claim 13, wherein the polysaccharide comprising a carboxylic acid group is selected from carboxymethyl cellulose and sodium carboxymethyl cellulose.

15. The encapsulated composition of claim 14, wherein the carboxymethyl cellulose and / or sodium carboxymethyl cellulose has a molecular weight of 50,000 to 250,000 g / mol and a degree of substitution of 0.5 to 1.

5.

16. The encapsulated composition of claim 1, wherein the first polyelectrolyte is a protein, the second polyelectrolyte is selected from methylcellulose and sodium carboxymethylcellulose, and wherein the weight ratio of the carboxymethylcellulose and / or sodium carboxymethylcellulose to the protein is 0.05 to 0.

2.

17. The encapsulated composition of claim 1, wherein the interface enabler is an aromatic dialdehyde or the interface enabler is derived from an aromatic dialdehyde.

18. The encapsulated composition of claim 1, wherein the interface enabler is a dialdehyde or the interface enabler is derived from a dialdehyde, wherein the dialdehyde is selected from 1,3-phenylenedialdehyde, 1,3-cyclohexanedialdehyde, cyclopentane-1,3-dialdehyde, furan-2,5-dialdehyde and 1,4-dicarboxypiperazine.

19. The encapsulated composition of claim 1, wherein the interface enabler is present at a level of 0.1 to 5 wt.% based on the weight of the core composition.

20. The encapsulated composition of claim 7, wherein the weight ratio of the interface enabler to the protein is 0.01 to 0.

1.

21. The encapsulated composition of claim 1, wherein the beneficial agent contained in the core or core composition is selected from fragrance ingredients, cosmetic ingredients, and bioactive ingredients.

22. The encapsulated composition of claim 1, comprising a plurality of core-shell microcapsules, wherein the median volume diameter Dv(50) of said microcapsules is 1 to 150 μm.

23. A method for preparing an encapsulated composition according to any one of claims 1 to 22, the method comprising the following steps: a) Provide a core composition comprising an interface enabler or a material from which an interface enabler can be derived; b) Provide an aqueous phase comprising the first and second polyelectrolytes; c) Emulsify the core composition provided in step a) into the aqueous phase provided in step b) to obtain core composition droplets dispersed in the aqueous phase, the core composition droplets having a median volume diameter of 1 to 100 μm; d) Lower the pH until the coagulation pH is reached, thereby forming a slurry of core-shell microcapsules; e) Add an additional crosslinking agent and keep the slurry under stirring to obtain a slurry of crosslinked microcapsules.

24. The method of claim 23, wherein in step b), the aqueous phase is provided at a pH of 5 to 13.

25. The method of claim 23 or 24, wherein in step b), the protein is dissolved in the aqueous phase at a temperature of 45 ± 5 °C.

26. The method of claim 23, wherein in step b), the polysaccharide is dissolved in the aqueous phase at a temperature of 45 ± 5 °C.

27. The method of claim 23, wherein in step c), the emulsion is obtained at a temperature of 30 to 60°C.

28. The method of claim 23, wherein in step e), the additional crosslinking agent is added at a temperature of 30 to 60°C, and the reaction is carried out for 1 to 20 hours.

29. The method of claim 23, wherein in step e), the additional crosslinking agent is selected from glutaraldehyde and transglutaminase.

30. An encapsulated composition obtainable by any one of claims 23 to 29.

31. Use of an interface enabler in a composition that yields the encapsulation of any one of claims 1 to 22 or 30.

32. A consumer product comprising a composition encapsulated according to any one of claims 1 to 22 or 30.

33. The consumer product of claim 32, wherein the consumer product is a fabric care product, a home care product, or a personal care product.

34. Use of the encapsulated composition of any one of claims 1 to 22 or 30 in obtaining a consumer product.

Images